Skip to content

Viome Precision Nutritional Programs to Improve Clinical Outcomes for Mental Health Disorders

Testing the Efficacy of Viome-designed Condition-based Supplements and Viome Precision Supplements to Improve Clinical Outcomes for Mental Health Conditions

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06502717
Enrollment
150
Registered
2024-07-16
Start date
2024-07-08
Completion date
2025-12-31
Last updated
2025-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety, Depression, Mental Health Issue

Keywords

mental health, diet, supplements, vitamins, stress

Brief summary

US residents who have mental health issues sign the informed consent form and are screened and enrolled for this study. Participants complete a survey upon enrollment and are randomized into one of two study arms. This study is direct to participant and will NOT utilize clinical sites.

Detailed description

Participants who meet the eligibility criteria are randomized into any of the two study arms including: the placebo arm or the VIOME Precision Nutrition Program (VPNP) arm. Placebo and Viome's Precision Nutrition Program include supplements, may include dietary recommendations towards improving the symptoms associated with mental health. The trial will last approximately 4 months for each participant.

Interventions

Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.

Sponsors

Viome
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

Once enrolled, participants are randomized into one of the two arms. The coded supplements with blinded labels are shipped to the participants. The participants are not aware of which group they are randomized into.

Intervention model description

Randomized, blinded, cohort study divided into two study arms: 1) control group (placebo), 2) precision-supplement

Eligibility

Sex/Gender
ALL
Age
25 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Resident of the United States * Females and males ages 25-75 (inclusive) * Able to speak and read English * No unexplained weight loss, fevers, anemia, or blood in stool * Willing and able to follow the trial instructions, as described in the recruitment letter * Signed and dated informed consent prior to any trial-specific procedures. * PHQ9 score of 5-24 (inclusive)

Exclusion criteria

* Unwilling to change their current diet * Prior use of Viome products or services * Antibiotic use in the previous 4 weeks * Pregnancy (current or planned in the next 4 months) * \< 90 days postpartum * Breast feeding * Active infection * Unable or unwilling to use Viome's App on an iPhone or Android smartphone * Significant diet or lifestyle change in the previous 1 month * IBD diagnosis -Major psychiatric/DSM-4 disease diagnosis (e.g. Schizophrenia, Bipolar disorder, Post- traumatic Stress Disorder, Obsessive Compulsive disorder) * Use of investigational drugs, products or devices within 1 month prior to and 4 months after the start of the trial * Cancer therapy within the previous 1 year * Major surgery in the last 6 months or planned in the next 4 months * Allergies to any supplement ingredients listed in the screening survey * Currently on a specific diet: FODMAP, KETO, PALEO * Answered yes to the question, In the past few weeks, have you wished you were dead or had thoughts about killing yourself? * Gastrointestinal disease including: * GI surgery except: * Appendectomy and benign polypectomy * Esophagitis * Celiac disease * GI malignancy or obstruction * Peptic Ulcer Disease * Duodenal or gastric ulcer disease

Design outcomes

Primary

MeasureTime frameDescription
Reduced GAD-7 Score~4 monthsReduced GAD-7 score for the VPNP groups compared to baseline scores.
Reduced PHQ-9 Score~4 monthsReduced PHQ-9 score for the VPNP group compared to baseline scores.
Reduced Perceived Stress Scale Score~4 monthsReduced Perceived Stress Scale score for the VPNP group compared to baseline scores.
Increased Quality of Life Score~4 monthsIncreased quality of life score for the VPNP group compared to baseline scores.
Correlation between microbial changes and clinical outcomes~4 monthsCorrelation between microbial changes on the VPNP with clinical outcomes.

Countries

United States

Contacts

Primary ContactMory Mehrtash
studies@viome.com(425) 300-6933
Backup ContactMomchilo Vuyisich
studies@viome.com(425) 300-6933

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026